Frank Theodor Peters

Frank Theodor Peters

Auto-generated profile, based on publicly available information

Frank Theodor Peters

Institute of Forensic Medicine, Jena University Hospital, Friedrich-Schiller-University Jena, Jena, Germany

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

2 May 2012 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
FPFrank T. Peters
Frank T. Peters
DRDaniela Remane
Daniela Remane

1 September 2016 in Clinical Biochemistry
Verified
Journal Article
Closed access
DRDaniela Remane
Daniela Remane
DWDirk K. Wissenbach
Dirk K. Wissenbach
FPFrank T. Peters
Frank T. Peters

14 June 2011 in Drug Testing and Analysis
Verified
Journal Article
Closed access
PDF file
FPFrank T. Peters
Frank T. Peters
MMMarkus R. Meyer
Markus R. Meyer

1 October 2010 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
FPFrank T Peters
Frank T Peters
JMJorge Ariel Martínez-Ramírez
Jorge Ariel Martínez-Ramírez
The emergence of ever new drugs of abuse on the illicit drug market is an ongoing challenge for analytical toxicologists. Because most of these new drugs or drug classes are not detected by established analytical methods targeting classic drugs of abuse, analytical procedures must be adapted or new procedures must be developed to cover these new compounds. This review summarizes the analytical toxicology of the following classes of emerging drugs of abuse: piperazines, phenethylamines (2Cs and FLYs), 4-substituted amphetamines, β-keto-amphetamines, 2,5-dimethoxy-amphetamines, pyrrolidinophenones, and synthetic cannabinoids.

16 December 2018 in WIREs Forensic Science
Verified
Journal Article
Open access
PDF file
FPFrank T. Peters
Frank T. Peters
ASAndrea E. Steuer
Andrea E. Steuer
When interpreting postmortem analytical data, toxicologists must be aware that postmortem concentrations of xenobiotics and/or their metabolites may be influenced by many factors. Some of these influences occur antemortem like the general pharmacokinetic properties of the xenobiotic or individual pharmacokinetics in the particular subject. They determine the concentrations at the time of death and may be relevant for the determination of the manner rather than the cause of death. Other influences occurring postmortem include continuing drug metabolism, chemical, and/or microbial degradation as well as potential postmortem formation of some toxicologically relevant compounds. Such postmortem effects may tremendously change the concentrations of xenobiotics and/or their metabolites at the time of death. If not adequately considered, this may lead to false conclusions regarding the involvement of the respective xenobiotic in the cause of death. The present article will provide an overview on antemortem and postmortem effects giving examples from the literature. It will also discuss if and how such effects may be identified based on postmortem specimens and, in case of the postmortem effects, how they may be reduced by proper storage and addition of stabilizers like fluoride salts.This article is categorized under: Toxicology > Post‐Mortem Toxicology Toxicology > Analytical Toxicology Toxicology > Drug Stability